WallStSmart

Azenta Inc (AZTA)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 828% more annual revenue ($5.54B vs $596.48M). RMD leads profitability with a 27.4% profit margin vs -29.1%. AZTA appears more attractively valued with a PEG of 0.53. RMD earns a higher WallStSmart Score of 73/100 (B).

AZTA

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 2.0Value: 7.7Quality: 8.5
Piotroski: 5/9Altman Z: 4.65

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.0Value: 4.7Quality: 9.5
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZTAUndervalued (+31.0%)

Margin of Safety

+31.0%

Fair Value

$44.14

Current Price

$22.69

$21.45 discount

UndervaluedFair: $44.14Overvalued
RMDSignificantly Overvalued (-26.9%)

Margin of Safety

-26.9%

Fair Value

$204.63

Current Price

$196.04

$8.59 premium

UndervaluedFair: $204.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZTA5 strengths · Avg: 9.6/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

EPS GrowthGrowth
8778.0%10/10

Earnings expanding 8778.0% YoY

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.6510/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.538/10

Growing faster than its price suggests

RMD5 strengths · Avg: 9.4/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.4%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Areas to Watch

AZTA4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
1.0%4/10

1.0% revenue growth

Market CapQuality
$1.05B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-11.5%2/10

ROE of -11.5% — below average capital efficiency

Profit MarginProfitability
-29.1%1/10

Currently unprofitable

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : AZTA

The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. PEG of 0.53 suggests the stock is reasonably priced for its growth.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : AZTA

The primary concerns for AZTA are Revenue Growth, Market Cap, Return on Equity.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

AZTA profiles as a turnaround stock while RMD is a mature play — different risk/reward profiles.

AZTA carries more volatility with a beta of 1.40 — expect wider price swings.

RMD is growing revenue faster at 10.8% — sustainability is the question.

RMD generates stronger free cash flow (520M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (73/100 vs 56/100), backed by strong 27.4% margins and 10.8% revenue growth. AZTA offers better value entry with a 31.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Azenta Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Azenta Inc. is a leading provider of sample management solutions and life science tools focused on improving laboratory efficiencies for biotechnology and pharmaceutical sectors. The company specializes in innovative automation, comprehensive biorepository services, and advanced storage technologies, empowering clients to expedite drug discovery while ensuring compliance with regulatory standards. With a robust strategy centered on cutting-edge technology and strategic collaborations, Azenta is strategically positioned to capitalize on growth opportunities within the expanding global life sciences market, thereby reinforcing its competitive edge in biobanking and sample management. Its unwavering commitment to advancing scientific research through sophisticated products further enhances its appeal to institutional investors seeking exposure to the dynamic life sciences landscape.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?